Ani Pharmaceuticals (ANIP) reported $883M in revenue for fiscal 2025, +43.8% year on year. That ranks #1848 by revenue among 2853 SEC filers and #169 in Healthcare. Net income was $78.0M, a net margin of 8.8%. Revenue has grown 72.3% a year on average since 2011 ($435,160 then). The fiscal 2025 balance sheet shows $1.4B in total assets, $286M in cash and $292M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $883M | +43.8% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $111M | +18,922.8% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $78.0M | +$97.0M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $185M | +189.3% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $13.8M | −14.8% | FY20252025-12-31 |
| Total assetsAssets | $1.4B | +12.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $541M | +33.9% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $286M | +97.1% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $292M | −5.6% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $237M | $29.5M | Open → |
| Q2 20262026-06-30 | $266M | $24.7M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Ani Pharmaceuticals Inc
- Ticker
- ANIP
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001023024
Filings
- 10-QAug 7, 2026Open filing →
- 10-QMay 8, 2026Open filing →
- 10-KFeb 27, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Usana Health SciencesUSNA | $925M | $10.8M |
| Tilray BrandsTLRY | $915M | −$121M |
| Inspire Medical SystemsINSP | $912M | $145M |
| Ani PharmaceuticalsANIP | $883M | $78.0M |
| Biocryst PharmaceuticalsBCRX | $875M | $264M |
| Warby ParkerWRBY | $872M | $1.6M |
| NeogenNEOG | $870M | −$7.9M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Ani Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/ani-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Ani Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/ani-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-ani-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Ani Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/ani-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001023024-26-000014 · February 27, 2026
{{cite web |title=Ani Pharmaceuticals — Key figures — 10-K (0001023024-26-000014) |url=https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-27}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.